Reference — Pharmacology
Anticoagulant Comparison Reference
Anticoagulants differ significantly in mechanism, route, monitoring requirements, and reversal options. This reference provides a side-by-side comparison of the major anticoagulants used in clinical nursing practice.
Educational use only. Anticoagulant dosing, monitoring intervals, and reversal agent selection are individualized and provider-ordered. Independent double-check is required at most facilities. Always follow your institution's anticoagulation protocols. This material supports nursing education and exam review. It is not medical advice and is not a substitute for clinical judgment, institutional policy, or medical direction. Always follow facility protocols and current provider orders.
Anticoagulant Comparison
| Drug | Route | Monitoring | Reversal Agent | Key Nursing Considerations |
|---|---|---|---|---|
| Heparin (UFH) | IV continuous infusion or SQ | aPTT (target 60–100 sec); platelets every 2–3 days (HIT surveillance) | Protamine sulfate | Use smart pump; weight-based dosing; monitor for HIT (platelet drop >50% = stop all heparin); titrate per aPTT protocol |
| Enoxaparin (LMWH) | Subcutaneous injection | Anti-Xa levels (if renal impairment, obesity, pregnancy); routine monitoring not required for standard dosing | Protamine sulfate (partial reversal ~60%) | Rotate abdomen sites; do not expel air bubble; reduce dose for CrCl <30 mL/min; do not rub after injection |
| Warfarin | Oral | INR (target 2.0–3.0 for most; 2.5–3.5 for mechanical valves); daily until stable, then weekly/monthly | Vitamin K (oral or IV), FFP (urgent), 4-factor PCC (rapid) | Check INR before each dose; extensive drug/food interactions; consistent vitamin K diet; delayed onset/offset (days) |
| Apixaban (Eliquis) | Oral (twice daily) | No routine coagulation monitoring; periodic renal function | Andexanet alfa (Andexxa) | No dietary restrictions unlike warfarin; fewer drug interactions; reduced dosing for renal impairment; do not crush tablets |
| Rivaroxaban (Xarelto) | Oral (once or twice daily) | No routine coagulation monitoring; periodic renal function | Andexanet alfa (Andexxa) | Take 10 mg+ doses with evening meal for absorption; avoid in severe renal impairment; fewer drug interactions than warfarin |
| Dabigatran (Pradaxa) | Oral (twice daily) | No routine monitoring (aPTT unreliable); renal function every 3–6 months | Idarucizumab (Praxbind) — complete reversal in minutes | Do not crush capsules; GI side effects common (take with food); renally cleared — contraindicated in severe renal impairment (CrCl <15) |
Common Indications
| Indication | Commonly Used Agents |
|---|---|
| Acute DVT/PE treatment | Heparin IV (initial), then transition to DOAC or warfarin |
| DVT/PE prevention (prophylaxis) | Enoxaparin SQ, heparin SQ (low-dose) |
| Atrial fibrillation (stroke prevention) | Apixaban, rivaroxaban, dabigatran; warfarin (if preferred or DOAC contraindicated) |
| Mechanical heart valve | Warfarin (DOACs not indicated for mechanical valves) |
| ACS / Cardiac catheterization | Heparin IV or enoxaparin IV/SQ |
Heparin-Induced Thrombocytopenia (HIT)
HIT is a serious immune-mediated adverse effect of heparin therapy. Paradoxically, platelet activation causes life-threatening thrombosis despite thrombocytopenia.
- Timing: Typically occurs 5–14 days after heparin exposure (or sooner with recent prior heparin exposure)
- Diagnostic criteria: Platelet count drop of > 50% from baseline; new thrombosis; no other explanation for thrombocytopenia
- Immediate action: Discontinue ALL heparin products — including heparin flushes and heparin-coated catheters. Do not switch to LMWH (cross-reactivity exists).
- Alternative anticoagulation: Switch to argatroban (IV direct thrombin inhibitor) or fondaparinux — provider ordered
- Do not give platelets: Platelet transfusion can worsen thrombosis in HIT
Bleeding Assessment & Precautions
- Assess for bleeding at every interaction: bruising, prolonged bleeding from puncture sites, epistaxis, hematemesis, melena, hematuria
- Neurological changes (sudden headache, altered consciousness) → intracranial bleed — emergency response
- Apply pressure for ≥ 5 minutes to all venipuncture sites
- Use soft-bristle toothbrush and electric razor
- Avoid IM injections and arterial punctures in anticoagulated patients when possible
- Fall prevention bundle mandatory for all anticoagulated patients
Related Resources
Standards & sources
Fact-checked Jun 20, 2026This page is written to align with Institute for Safe Medication Practices (ISMP) · FDA prescribing information · The Joint Commission — National Patient Safety Goals. It is an educational summary, not a citation of any single document — always verify specific doses, values, and protocols against current guidelines and your facility policy. How we source content →